Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Medicinus : Jurnal Kedokteran
Romano, Sultan Adhitya
Unknown Affiliation
Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Therapeutic Potential of Neural Stem Cell in Ischemic Stroke: A Systematic Review Periyanto, Toni; Putri, Evira Agustina; Romano, Sultan Adhitya; Riantiarno, Chairizia; Kamal, M. Aulady Rifki; Aulia, Indri Noer; Sugianto, Michael Aquilar
Medicinus Vol. 14 No. 3 (2025): June
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v14i3.10165

Abstract

Background: Ischemic stroke remains a leading cause of disability and mortality worldwide, with over 12 million new cases annually and limited treatment options confined to narrow therapeutic windows. Neural stem cells (NSCs) have emerged as a promising therapeutic avenue due to their ability to self-renew, differentiate into all neural lineages, and exert paracrine effects that modulate inflammation and promote neurogenesis. Preclinical studies have demonstrated functional improvements of up to 60% in animal stroke models, but a systematic evaluation of these findings is needed to inform future clinical applications. Methods: A systematic review was conducted following PRISMA 2020 guidelines. Databases searched included PubMed, EMBASE, and Scopus, covering literature up to May 8, 2025. Inclusion criteria comprised in vivo preclinical studies investigating NSC transplantation in animal models of ischemic stroke with at least one neurological, infarct, or histological outcome. Data extraction and risk of bias assessment (ROBINS-I) were independently performed by three reviewers. Due to study heterogeneity, a narrative synthesis was undertaken. Result: Eight studies met the inclusion criteria. NSC therapy improved neurological recovery in over 80% of cases, reduced infarct volume by up to 40%, and downregulated pro-inflammatory and apoptotic markers. Benefits were dose- and timing-dependent, with intracerebral and intravenous routes demonstrating variable efficacy. One study reported tumorigenicity, highlighting the need for safety profiling. Conclusions: Preclinical evidence supports the therapeutic potential of NSCs in ischemic stroke through neuroprotective and neurorestorative mechanisms. High-certainty findings justify continued investigation in clinical trials to refine dosing, delivery, and safety protocols.
Efficacy and Safety of Stem Cell Therapy for Spinal Cord Injury in Adults: A Systematic Review and Meta-Analysis Rhadika, Anadya; Romano, Sultan Adhitya; Widyatmiko, Himawan; Tanuwijaya, Andrew Wilbert; Putra, Putu Surya Pradipta Hariantha; Amanah, Salma Rizqi; Elashry, Abdelrahman Ramadan; Javaid, Sarmad; Inggas, Made Agus Mahendra; Wijaya, Jeremiah Hilkiah
Medicinus Vol. 15 No. 1 (2025): October
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v15i1.10762

Abstract

Background: Despite encouraging early results, clinical outcomes remain inconsistent across trials. This study aimed to systematically evaluate the efficacy and safety of stem cell therapy in adults with spinal cord injury (SCI). Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, EMBASE, and Scopus were searched until 18 October 2025. Eligible studies included adult SCI patients receiving stem cell therapy with measurable neurological outcomes. Data synthesis was performed using Review Manager 5.4 under a random-effects model, reporting pooled risk ratios (RR) with 95% confidence intervals (CIs). Risk of bias was assessed using ROBINS-I, and evidence certainty was graded via GRADE. Result: Thirteen studies involving 470 participants (286 intervention, 184 control) were included. Stem cell therapy significantly improved neurological recovery compared with controls (RR = 2.64; 95% CI 1.70–4.10; p < 0.0001; I² = 0%). Subgroup analyses showed consistent benefits across baseline AIS classifications (RR = 2.61; 95% CI 1.71–3.98) and cell doses (RR = 2.75; 95% CI 1.63–4.64). No major safety signals were identified. GRADE assessment rated the certainty of efficacy evidence as moderate. Conclusions: Stem cell therapy yields significant neurological improvement in adult SCI with a favorable safety profile. The findings support its regenerative potential through neuroprotective and remyelinating mechanisms. However, larger randomized controlled trials are required to validate efficacy, optimize protocols, and assess long-term safety.
Co-Authors Amanah, Salma Rizqi Aulia, Indri Noer Elashry, Abdelrahman Ramadan Javaid, Sarmad Kamal, M. Aulady Rifki Made Agus Mahendra Inggas, Made Agus Mahendra Periyanto, Toni Putra, Putu Surya Pradipta Hariantha Putri, Evira Agustina Rhadika, Anadya Riantiarno, Chairizia Sugianto, Michael Aquilar Tanuwijaya, Andrew Wilbert Widyatmiko, Himawan Wijaya, Jeremiah Hilkiah